Biotechnology & Medical Research
Stemline Therapeutics says SL-401 Phase 2 trial in AML results found SL-401 to be safe, well tolerated
Stemline Therapeutics Inc : SL-401 was found to be safe and well tolerated, and side effects were predictable and manageable .Stemline Therapeutics presents SL-401 lead-in results from its ongoing Phase 2 trial in AML in remission with MRD and Phase 2 trial in high-risk myeloproliferative neoplasms...
Kiadis Pharma NV : Presents positive 1-year follow-up data of its pivotal Phase II Trial with ATIR101 . Significant reduction in Transplant Related Mortality and improvement in Overall Survival observed in comparison to an observational control group .Zero patients developed grade III-IV acute...
Oryzon Genomics SA : Presented on Monday the results from Phase I / IIA clinical trial with ORY-1001 in patients with recurrent or refractory acute leukaemia . The preliminary conclusions show that ORY-1001 is a highly active LSD1 inhibitor with strong differentiation-inducing activity in patients...
No related earnings announcements are currently scheduled within the next 7 days.